|
|
|
| Antitrust Regulation toward Patent Reverse Payment Settlement:Experience in the United States and Its Implications |
| Sun Yuchen |
| (Law School, Renmin University of China, Beijing 100872,China) |
|
|
|
|
Abstract In the pharmaceutical industry of the United States, the patent litigation settlement agreement which includes reverse payments from the patent holder to the alleged infringer, has aroused widespread concern. The typical purpose of this agreement is as exchange for the alleged infringer's agreement to delay or abandon market entry. The agreement is the by-product of the patent linkage system. The Supreme Court analyzed this agreement under the traditional rule of reason and hoped to reduce the cost of mistake by comprehensively evaluating various factors. However, due to the limitations of the rule of reason, the presumptive illegality approach would presumably become the most appropriate rule in the United States. In China's context, the reverse-payment agreement should be analyzed under the prohibition and exemption framework, in order to achieve the balance of competition order maintenance, innovation incentives and other values.
|
|
Received: 06 June 2019
|
|
|
|
|
|
[1] LAURA J ROBINSON.Analysis of recent proposals to reconfigure hatch-waxman[J].Journal of Intellectual Property Law,2003,11(1):7-48.
[2] HENRY N BUTLER，JEFFREY PAUL JAROSCH.Policy reversal on reverse payments:why courts should not follow the new DOJ position on reverse-payment settlements of pharmaceutical patent litigation[J].Iowa Law Review,2010,96(1):108.
[3] MICHAEL A CARRIER.Solving the drug settlement problem:the legislative approach[J].Rutgers Law Journal,2009,41(1&2):97-98.
[4] CORY J INGLE.Reverse payment settlements:a patent approach to defending the argument for illegality[J].I/S:A Journal of Law and Policy,2011,7(2):534.
[5] ZHENGHUI WANG.Reanalyzing reverse payment settlements:a solution to the patentee's dilemma[J].Cornell Law Review,2014,99(5):1239.
[6] MICHAEL A CARRIER.Why the cope of the patent test cannot solve the drug patent settlement problem[J].Stanford Technology Law Review,2012,16(1):2-6.
[7] KIMBERLY A MOORE.Judges,juries,patent cases:an empirical peek inside the black box[J].Michigan Law Review,2000,96(2):385.
[8] CARL SHAPIRO.Antitrust limits to patent settlements[J].RAND Journal of Economics,2003,34:391-395.
[9] HERBERT HOVENKAMP,MARK JANIS，MARK A LEMLEY.Anticompetitive settlement of intellectual property disputes[J].Minnesota Law Review,2003,87(6):1735.
[10] DAVID W OPDERBECK.Rational antitrust policy and reverse payment settlements in hatch-waxman patent litigation[J].The Georgetown Law Journal,2010,98(5):1329-1333.
[11] THOMAS F COTTER.FTC v Actavis,inc:when is the rule of reason not the rule of reason[J].MINN.J.L.SCL & TECH,2014（15）:41-49.
[12] [美]克里斯蒂娜·博翰楠,赫伯特·霍温坎普.创造无羁限：促进创新中的自由与竞争[M].兰磊，译.北京:法律出版社,2016:106.
[13] 严仁群.“消失中的审判”？——重新认识美国的诉讼和解与诉讼调解[J].现代法学,2016(5):165.
[14] 白光清.药品专利之战[M].北京:知识产权出版社,2018:21.
[15] 苏华,韩伟.药业反向支付协议反垄断规制的最新发展——兼评Actavis案及Lundbeck案[J].工商行政管理,2013(16):38-41.
[16] MICHAEL CLANCY,DAMIEN GERADIN,ANDREW LAZEROW.Reverse-payment patent settlements in the pharmaceutical industry:an analysis of us antitrust law and eu competition law[J].The Antitrust Bulletin,2014,59(1):163-164.
[17] MICHAEL A CARRIER.Drug patent settlements around the world[J].The Antitrust Bulletin,2017,62(4):770-785.
[18] SEIKO F OKADA.In re k-dur antitrust litigation:pharmaceutical reverse payment settlements go beyond the scope of the patent[J].North Carolina Journal of Law & Technology,2012,14(1):307.
[19] [美]赫伯特·霍温坎普.反竞争性专利和解协议与最高法院对阿特维斯案的判决[J].孙瑜晨,译.竞争政策研究,2019(2):56-73.
[20] 陶冠东.反向支付的反垄断法适用[J].竞争政策研究,2017(3):86.
[21] 叶卫平.反垄断法分析模式的中国选择[J].中国社会科学,2017(3):96.
[22] MICHAEL A CARRIER.The real rule of reason:bridging the disconnect[J].Brigham Young University Law Review,2006（1999）:1265.
[23] JOSHUA P DAVIS.Applying litigation economics to patent settlements:why reverse payments should be per se illegal[J].Rutgers Law Journal,2009,41(1&2):258-261.
[24] 时建中,郝俊淇.原则性禁止转售价格维持的立法正确性及其实施改进[J].政治与法律,2017(11):20-33.
|
|
|
|
